0001562180-20-006251.txt : 20201002 0001562180-20-006251.hdr.sgml : 20201002 20201002200504 ACCESSION NUMBER: 0001562180-20-006251 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200930 FILED AS OF DATE: 20201002 DATE AS OF CHANGE: 20201002 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Kalb Michael Wayne CENTRAL INDEX KEY: 0001678248 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21392 FILM NUMBER: 201222018 MAIL ADDRESS: STREET 1: 24 LUCILLE LANE CITY: DIX HILLS STATE: NY ZIP: 11746 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMARIN CORP PLC\UK CENTRAL INDEX KEY: 0000897448 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: X0 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C STREET 2: 77 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 BUSINESS PHONE: 353 1 6699 020 MAIL ADDRESS: STREET 1: SPACES SOUTH DOCKLANDS, BLOCK C STREET 2: 77 SIR JOHN ROGERSON'S QUAY CITY: DUBLIN 2 STATE: L2 ZIP: D02 VK60 FORMER COMPANY: FORMER CONFORMED NAME: AMARIN PHARMACEUTICALS PLC DATE OF NAME CHANGE: 20000201 FORMER COMPANY: FORMER CONFORMED NAME: ETHICAL HOLDINGS PLC DATE OF NAME CHANGE: 19930322 4 1 primarydocument.xml PRIMARY DOCUMENT X0306 4 2020-09-30 false 0000897448 AMARIN CORP PLC\UK AMRN 0001678248 Kalb Michael Wayne C/O AMARIN PHARMA, INC. 440 US HIGHWAY 22 BRIDGEWATER NJ 08807 false true false false SVP and CFO Ordinary Shares 2020-09-30 4 M false 1528.00 A 95385.00 D Ordinary Shares 2020-09-30 4 M false 1528.00 A 96913.00 D Restricted Stock Units 0.00 2020-09-30 4 M false 1528.00 0.00 D Ordinary Shares 1528.00 16805.00 D Restricted Stock Units 0.00 2020-09-30 4 M false 1528.00 0.00 D Ordinary Shares 1528.00 16805.00 D The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. As previously reported on February 27, 2020, on May 15, 2017, the Reporting Person was granted 220,000 Restricted Stock Units ("RSUs") under the Amarin Corporation plc Stock Incentive Plan (the "Plan"), of which the performance criteria related to two tranches representing 50% of the total award was deemed achieved on February 25, 2020 pursuant to reporting of audited net product revenues for 2019 exceeding $400 million. The tranches vest ratably over 36 months beginning September 30, 2018 subject to achievement of the performance criteria and continued employment of the Reporting Person as provided in the RSU Award Agreement between the Issuer and Reporting Person. The twenty-fifth vesting event occurred on September 30, 2020. The performance criteria related to the remaining 50% tranche has not yet been achieved; such tranche has not lapsed as a result of achieving the other two tranches. Not applicable. Please see the section titled "Remarks" below for additional information. Each RSU represents a contingent right to receive one Ordinary Share or cash in lieu thereof at the Issuer's discretion. As of the date of this Form 4, the Reporting Person owns or holds the right to acquire an aggregate of 928,389 Ordinary Shares of the Issuer in the form of Ordinary Shares, stock options and RSUs granted under the Plan, including but not limited to certain performance-based RSUs that are earned only if product revenues reach pre-defined annual milestone levels and, in certain cases, then vest only if the recipient remains with the company for an extended period of time. /s/ Joseph T. Kennedy, by power of attorney 2020-10-02